Tag Archives: Janssen Pharmaceuticals

October, 2017

April, 2017

  • 10 April

    Janssen and PeptiDream Enter $1.15 Billion Drug Discover Deal

    TOKYO–(BUSINESS WIRE)–PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO: 4587) announced today that it has entered into a multi-target discovery and optimization collaboration with US-based Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ). Under the agreement, facilitated by Johnson & Johnson Innovation, …

July, 2015

  • 8 July

    Short and Sweet

    A treatment timeline of 52 weeks to clear the hepatitis C virus from the body, thankfully, is a thing of the past. Today, treatment horizons continue to get shorter and shorter for hepatitis C infections, with 12 weeks currently being a very typical treatment time for most hepatitis C patients. …

May, 2015

  • 19 May

    Janssen and Achillion Enter $1.1 Billion Hepatitis C Deal

    Janssen Pharmaceuticals, Inc. has agreed to pay up to $1.1 billion for the rights to Achillion Pharmaceuticals’ pipeline of hepatitis C virus (HCV) assets. The company announced that it has entered into an exclusive worldwide license and collaboration arrangement with Achillion Pharmaceuticals to develop and commercialize one or more of …